Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data

The landscape of treatment for multiple myeloma (MM) has significantly changed over the last decade due to novel agents that have shown superiority in efficacy such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) over traditional therapies. However, the real‐world utilization of th...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer medicine (Malden, MA) Vol. 9; no. 2; pp. 626 - 639
Main Authors:	Goto, Daisuke, Khairnar, Rahul, Yared, Jean A., Yong, Candice, Romanus, Dorothy, Onukwugha, Eberechukwu, Slejko, Julia F.
Format:	Journal Article
Language:	English
Published:	United States John Wiley & Sons, Inc 01.01.2020 John Wiley and Sons Inc Wiley
Subjects:	Age Aged Aged, 80 and over Algorithms Alkylating agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bone lesions Cancer therapies Clinical Cancer Research Clinical trials Datasets Disease elderly patients Epidemiology Female Follow-Up Studies Geriatrics Humans Hypercalcemia Immunomodulation Immunomodulators immunomodulatory drugs (IMiDs) Immunosuppressive agents Male Medicare Medicare - statistics & numerical data Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - epidemiology Multiple Myeloma - pathology Original Research Patients Prognosis Proteasome inhibitors Renal failure Retrospective Studies SEER Program - statistics & numerical data SEER‐Medicare Stem cell transplantation Stem cells Studies Survival Rate systemic treatment United States - epidemiology United States United States > US elderly patients proteasome inhibitors multiple myeloma systemic treatment SEER-Medicare immunomodulatory drugs (IMiDs)
ISSN:	2045-7634, 2045-7634
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!